Mandate

Vinge represents Lassie AB in a capital raising of SEK 260 million

November 29, 2023 M&A

Vinge has advised the pet insurance broker Lassie AB in connection with a capital raising of SEK 260 million in order to continue the expansion of the business.

Lassie AB, whose business model is based on users reducing their insurance costs by collecting points through preventive animal care, was founded by Hedda Båverud Olsson, Johan Jönsson and Sophie Wilkinson and the company has grown rapidly since the first capital round just over two years ago.

The capital round, which was led by the British venture capital firm Balderton Capital, also involved a number of existing investors, including the institutional investors Felix Capital, Inventure and Passion Capital.

Vinge's team consisted of Filip Öhrner and Tim Axell.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026